SUTRO BIOPHARMA, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Sutro Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q3 2024.
  • Sutro Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$48.8M, a 1.01% increase year-over-year.
  • Sutro Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$124M, a 28.1% increase year-over-year.
  • Sutro Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$107M, a 10.4% increase from 2022.
  • Sutro Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$119M, a 12.9% decline from 2021.
  • Sutro Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$106M, a 228% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$124M -$48.8M +$497K +1.01% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$124M -$48M -$9.49M -24.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$115M -$58.2M -$8.16M -16.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$107M $31.1M +$65.7M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$172M -$49.3M -$29.8M -153% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$143M -$38.5M -$12.5M -48.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$130M -$50.1M -$10.9M -28% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$119M -$34.6M +$3.53M +9.26% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$123M -$19.5M +$11.4M +36.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$134M -$26M -$19.9M -323% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$114M -$39.1M -$8.75M -28.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$106M -$38.1M +$21.4M +36% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-25
Q3 2021 -$127M -$30.9M -$48M -280% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$78.9M -$6.15M -$36M -121% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$42.9M -$30.4M -$10.8M -54.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$32.1M -$59.5M -$44.8M -303% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-18
Q3 2020 $12.6M $17.1M +$30.1M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$17.4M $29.9M +$43.7M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$61.1M -$19.6M -$5.35M -37.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$55.7M -$14.8M -$13.3M -891% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$42.4M -$12.9M -$2.68M -26.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-18
Q2 2019 -$39.8M -$13.8M -$2.25M -19.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-18
Q1 2019 -$37.5M -$14.3M -$2.2M -18.3% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-18
Q4 2018 -$35.3M -$1.49M +$13.9M +90.3% Oct 2, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$49.2M -$10.2M -$8.82M -622% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-16
Q2 2018 -$40.3M -$11.5M -$9.73M -537% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-16
Q1 2018 -$30.6M -$12M -$10.9M -981% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-16
Q4 2017 -$19.7M -$15.3M Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 -$1.42M Jul 1, 2017 Sep 30, 2017 10-K 2019-04-01
Q2 2017 -$1.81M Apr 1, 2017 Jun 30, 2017 10-K 2019-04-01
Q1 2017 -$1.11M Jan 1, 2017 Mar 31, 2017 10-K 2019-04-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.